Oliver DÃ¶rr

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9348773/publications.pdf

Version: 2024-02-01

80 papers	1,474 citations	361413 20 h-index	361022 35 g-index
83 all docs	83 docs citations	83 times ranked	2368 citing authors

#	Article	IF	Citations
1	Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. European Heart Journal, 2020, 41, 1890-1899.	2.2	159
2	Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (TranscatheteR HeArt Valve EmboLization and Migration). European Heart Journal, 2019, 40, 3156-3165.	2.2	92
3	General Versus Local Anesthesia With Conscious Sedation in Transcatheter Aortic Valve Implantation. Circulation, 2020, 142, 1437-1447.	1.6	81
4	Pacemaker implantation after TAVI: predictors of AV block persistence. Clinical Research in Cardiology, 2018, 107, 60-69.	3.3	71
5	Impact of the COVID-19 pandemic on cardiovascular mortality and catherization activity during the lockdown in central Germany: an observational study. Clinical Research in Cardiology, 2021, 110, 292-301.	3.3	63
6	Outcome after transvascular transcatheter aortic valve implantation in 2016. European Heart Journal, 2018, 39, 667-675.	2.2	61
7	Trends in aortic valve replacement in Germany in 2015: transcatheter versus isolated surgical aortic valve repair. Clinical Research in Cardiology, 2017, 106, 411-419.	3.3	52
8	Release Kinetics of Inflammatory Biomarkers in a Clinical Model of Acute Myocardial Infarction. Circulation Research, 2015, 116, 867-875.	4.5	51
9	Soluble fms-Like Tyrosine Kinase-1 and Endothelial Adhesion Molecules (Intercellular Cell Adhesion) Tj ETQq1 1 0.784314 rgBT /Overlock Reduction After Renal Sympathetic Denervation. Hypertension, 2014, 63, 984-990.	2.7	50
10	Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clinical Research in Cardiology, 2014, 103, 141-148.	3.3	49
11	Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of cardiac surgery associated acute kidney injury. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 392-399.	1.2	40
12	Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension. Clinical Research in Cardiology, 2015, 104, 175-184.	3.3	37
13	Plasma microRNA-21 for the early prediction of acute kidney injury in patients undergoing major cardiac surgery. Nephrology Dialysis Transplantation, 2016, 31, 760-766.	0.7	36
14	New potential diagnostic biomarkers for pulmonary hypertension. European Respiratory Journal, 2015, 46, 1390-1396.	6.7	32
15	Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA. Biomolecules, 2019, 9, 666.	4.0	30
16	Impact of Anesthesia Strategy and Valve Type on Clinical Outcomes After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2204-2215.	2.8	28
17	Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. International Journal of Cardiology, 2015, 179, 90-94.	1.7	26
18	Renal Sympathetic Denervation Does Not Aggravate Functional or Structural Renal Damage. Journal of the American College of Cardiology, 2013, 61, 479-480.	2.8	23

#	Article	IF	Citations
19	A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives. International Journal of Cardiology, 2017, 227, 127-133.	1.7	23
20	Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. Clinical Research in Cardiology, 2015, 104, 1064-1071.	3.3	21
21	Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clinical Research in Cardiology, 2016, 105, 755-762.	3.3	21
22	A multicenter postâ€marketing evaluation of the Elixir DESolve^{Â®} Novolimusâ€eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheterization and Cardiovascular Interventions, 2018, 92, 1021-1027.	1.7	21
23	N-terminal fragment of cardiac myosin binding protein-C triggers pro-inflammatory responses in vitro. Journal of Molecular and Cellular Cardiology, 2016, 99, 47-56.	1.9	20
24	Brain-Derived Neurotrophic Factor as aÂMarker for Immediate Assessment of the SuccessÂof Renal Sympathetic Denervation. Journal of the American College of Cardiology, 2015, 65, 1151-1153.	2.8	19
25	Transvascular transcatheter aortic valve implantation in 2017. Clinical Research in Cardiology, 2020, 109, 303-314.	3.3	18
26	Feasibility of Coronary Access in Patients With Acute Coronary Syndrome and Previous TAVR. JACC: Cardiovascular Interventions, 2021, 14, 1578-1590.	2.9	18
27	Impact of the learning curve on procedural results and acute outcome after percutaneous coronary interventions with everolimus-eluting bioresorbable scaffolds in an all-comers population. Cardiovascular Revascularization Medicine, 2015, 16, 455-460.	0.8	17
28	High-sensitivity cardiac troponin T and copeptin assays to improve diagnostic accuracy of exercise stress test in patients with suspected coronary artery disease. European Journal of Preventive Cardiology, 2015, 22, 684-692.	1.8	16
29	Safety and effectiveness of coronary intravascular lithotripsy in eccentric calcified coronary lesions: a patient-level pooled analysis from the Disrupt CAD I and CAD II Studies. Clinical Research in Cardiology, 2021, 110, 228-236.	3.3	16
30	Influence of Renal Sympathetic Denervation on Cardiac Extracellular Matrix Turnover and Cardiac Fibrosis. American Journal of Hypertension, 2015, 28, 1285-1292.	2.0	15
31	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. European Respiratory Journal, 2021, 57, 1901192.	6.7	15
32	Release kinetics of N-terminal pro-B-type natriuretic peptide in a clinical model of acute myocardial infarction. Clinica Chimica Acta, 2014, 429, 34-37.	1.1	12
33	Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the TreatmentÂof Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 477-485.	2.9	12
34	Aortic valve replacement in Germany in 2019. Clinical Research in Cardiology, 2021, 110, 460-465.	3.3	12
35	Specific biomarkers of myocardial inflammation and remodeling processes as predictors of mortality in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 481-487.	1.8	11
36	SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension. Biomarkers, 2020, 25, 290-295.	1.9	11

#	Article	IF	Citations
37	Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. International Journal of Cardiology, 2017, 246, 74-79.	1.7	10
38	Release kinetics of high-sensitivity cardiac troponins I and T and troponin T upstream open reading frame peptide (TnTuORF) in clinically induced acute myocardial infarction. Biomarkers, 2017, 22, 304-310.	1.9	10
39	Lower mortality in an all-comers aortic stenosis population treated with TAVI in comparison to SAVR. Clinical Research in Cardiology, 2020, 109, 611-615.	3.3	10
40	Identification of Periprocedural Myocardial Infarction Using a High-Sensitivity Troponin I Assay in Patients Who Underwent Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 1180-1186.	1.6	9
41	Implantation of everolimusâ€eluting bioresorbable scaffolds in a diabetic allâ€comers population. Catheterization and Cardiovascular Interventions, 2015, 86, 975-981.	1.7	8
42	IL10 Alters Peri-Collateral Macrophage Polarization and Hind-Limb Reperfusion in Mice after Femoral Artery Ligation. International Journal of Molecular Sciences, 2020, 21, 2821.	4.1	8
43	Reference Values and Release Kinetics of B-Type Natriuretic Peptide Signal Peptide in Patients with Acute Myocardial Infarction. Clinical Chemistry, 2015, 61, 1532-1539.	3.2	7
44	Bioresorbable scaffolds for the treatment of in-stent restenosis. Heart and Vessels, 2015, 30, 265-269.	1.2	7
45	Rescue baroreflex activation therapy after Stanford B aortic dissection due to therapy-refractory hypertension. Journal of the American Society of Hypertension, 2016, 10, 490-492.	2.3	7
46	A new novolimus-eluting bioresorbable scaffold for large coronary arteries: an OCT study of acute mechanical performance. International Journal of Cardiology, 2016, 220, 706-710.	1.7	7
47	Who Is Afraid of CRP? Elevated Preoperative CRP Levels Might Attenuate the Increase in Inflammatory Parameters in Response to Lung Cancer Surgery. Journal of Clinical Medicine, 2020, 9, 3340.	2.4	7
48	Initial experience with a novel, modular, minimalistic approach for transfemoral aortic valve implantation. International Journal of Cardiology, 2021, 332, 54-59.	1.7	7
49	Influence of Renal Sympathetic Denervation on Quality of Life. Journal of Interventional Cardiology, 2013, 26, 536-541.	1.2	6
50	Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions â€" Implications from early clinical experience during daily practice. Cardiovascular Revascularization Medicine, 2016, 17, 313-317.	0.8	6
51	Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects. Clinical Research in Cardiology, 2017, 106, 271-279.	3.3	6
52	Galectinâ€3 and ST2 as predictors of therapeutic success in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1164-1169.	1.8	6
53	Predictive value of preprocedural procalcitonin for short- and long-term mortality after transfemoral transcatheter aortic valve implantation. Heart and Vessels, 2019, 34, 1993-2001.	1.2	6
54	Myeloid-related protein 8/14 and high-sensitivity cardiac troponin I to differentiate type 2 myocardial infarction. International Journal of Cardiology, 2020, 304, 144-147.	1.7	6

#	Article	IF	Citations
55	Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodelingÂin pulmonary hypertension. Biomarkers in Medicine, 2021, 15, 1021-1034.	1.4	6
56	Biomarker response and therapy prediction in renal denervation therapy â€“ the role of MR-proadrenomedullin in a multicenter approach. Biomarkers, 2017, 22, 225-231.	1.9	5
57	Prognostic performance of the ESC SCORE and its German recalibrated versions in primary and secondary prevention. European Journal of Preventive Cardiology, 2020, 27, 2166-2169.	1.8	5
58	Anatomical suitability and off-label use of contemporary transcatheter heart valves. International Journal of Cardiology, 2022, 350, 96-103.	1.7	5
59	Evaluation of cystatin C and neutrophil gelatinaseâ€associated lipocalin as predictors of mortality in patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1474-1479.	1.8	4
60	Effect of Plaque Composition, Morphology, and Burden on DESolve Novolimus-Eluting Bioresorbable Vascular Scaffold Expansion and Eccentricity â€“ An Optical Coherence Tomography Analysis. Cardiovascular Revascularization Medicine, 2019, 20, 480-484.	0.8	4
61	Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. International Journal of Cardiology, 2020, 312, 42-47.	1.7	4
62	Fusion imaging guided implantation of a Tricento transcatheter heart valve for severe tricuspid regurgitation. Catheterization and Cardiovascular Interventions, 2021, 98, E780-E784.	1.7	4
63	Application and Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio in Patients with Ischemic and Non-Ischemic Cardiomyopathy. Diagnostics, 2021, 11, 2188.	2.6	4
64	Longâ€term verification of functional and structural renal damage after renal sympathetic denervation. Catheterization and Cardiovascular Interventions, 2016, 87, 1298-1303.	1.7	3
65	Micro-dislodgement of a self-expanding transcatheter heart valve: Incidence, predictors, and outcomes. International Journal of Cardiology, 2022, 358, 77-82.	1.7	3
66	Barostim Implantation with Ipsilateral Carotid Endarterectomy as a One-Stage Procedure. Annals of Vascular Surgery, 2016, 36, 295.e9-295.e11.	0.9	2
67	Outcome of thrombus aspiration in STEMI patients: a propensity score-adjusted study. Journal of Thrombosis and Thrombolysis, 2018, 45, 240-249.	2.1	2
68	First Experience with the New MitraClip NTR/XTR Device. Structural Heart, 2019, 3, 288-295.	0.6	2
69	Single versus double use of a suture-based closure device for transfemoral aortic valve implantation. International Journal of Cardiology, 2021, 331, 183-188.	1.7	2
70	Latest Developments in Robotic Percutaneous Coronary Intervention. Surgical Technology International, 0, , .	0.2	2
71	Transapical Coronary Artery Intervention. Circulation: Cardiovascular Interventions, 2012, 5, 446-447.	3.9	1
72	Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1144-1151.	0.6	1

#	Article	IF	Citations
73	Clinical presentation does not affect acute mechanical performance of the Novolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography. Postepy W Kardiologii Interwencyjnej, 2021, 17, 272-280.	0.2	1
74	First-in-Man Coronary Sinus Lead Stabilization Using a Bioresorbable Vascular Scaffold System. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1518-1519.	4.8	0
75	Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis. International Journal of Cardiology, 2017, 231, 73-77.	1.7	0
76	OCTâ€assessment of scaffold resorption: Analysis of strut intensity by a new resorption index for polyâ€lâ€lactic acid bioresorbable vascular scaffolds. Catheterization and Cardiovascular Interventions, 2019, 94, 928-935.	1.7	0
77	Anti-citrullinated protein antibodies are not associated with extent of disease or prognosis in patients with coronary artery disease. Clinical Chemistry and Laboratory Medicine, 2019, 57, e159-e161.	2.3	0
78	Fractional flow reserve and frequency of PCI in patients with coronary artery disease. Herz, 2020, 45, 752-758.	1.1	0
79	Fiveâ€year followâ€up of patients who underwent everolimusâ€eluting bioresorbable scaffold implantation. Catheterization and Cardiovascular Interventions, 2021, 97, 56-62.	1.7	0
80	Latest Developments in Robotic Percutaneous Coronary Intervention. Surgical Technology International, 2021, 38, 325-330.	0.2	0